As­cle­tis Phar­ma scraps liv­er dis­ease pro­gram; An­oth­er re­verse merg­er

Plus, news about Benev­o­len­tAI, Adap­tive Biotech­nolo­gies, Ei­sai, CNX Ther­a­peu­tics, Van­da Phar­ma­ceu­ti­cals and Nu­cle­ai:

As­cle­tis Phar­ma ends liv­er dis­ease pro­gram: The Chi­nese biotech will not pur­sue fur­ther de­vel­op­ment of ASC42 for pri­ma­ry bil­iary cholan­gi­tis af­ter Phase 2 da­ta sug­gest­ed a lack of com­pet­i­tive­ness ver­sus com­pet­ing can­di­dates. As­cle­tis al­so dropped clin­i­cal work on the FXR ag­o­nist in he­pati­tis B. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER